Ultimovacs ASA (OSL:ZLNA)

Norway flag Norway · Delayed Price · Currency is NOK
1.946
+0.014 (0.72%)
At close: Mar 28, 2025
-75.58%
Market Cap 393.62M
Revenue (ttm) n/a
Net Income (ttm) -201.06M
Shares Out 202.27M
EPS (ttm) -5.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 116,125
Average Volume 228,621
Open 1.900
Previous Close 1.932
Day's Range 1.900 - 2.000
52-Week Range 1.570 - 124.600
Beta 0.78
RSI 40.74
Earnings Date Apr 2, 2025

About Ultimovacs ASA

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Employees 12
Stock Exchange Oslo Børs
Ticker Symbol ZLNA
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.